These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22863599)

  • 21. Transdermal rotigotine in restless legs syndrome: impulse control disorders.
    Prescrire Int; 2014 Oct; 23(153):239. PubMed ID: 25964969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
    Naidu Y; Chaudhuri KR
    Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease].
    Katunina EA; Titova NV; Bezdolny YN; Shykkerimov RK; Gasanov MG; Burd SG; Lebedeva AV; Boiko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(5):34-40. PubMed ID: 26356158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study.
    Stiasny-Kolster K; Kohnen R; Schollmayer E; Möller JC; Oertel WH;
    Mov Disord; 2004 Dec; 19(12):1432-8. PubMed ID: 15390055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Saletu B; Trenkwalder C; Sommerville KW; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Mar; 9(3):228-39. PubMed ID: 17553743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.
    Dohin E; Högl B; Ferini-Strambi L; Schollmayer E; Fichtner A; Bauer L; García-Borreguero D
    Expert Opin Pharmacother; 2013 Jan; 14(1):15-25. PubMed ID: 23256574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The development of the rotigotine transdermal patch: a historical perspective.
    Waters C
    Neurol Clin; 2013 Aug; 31(3 Suppl):S37-50. PubMed ID: 23931953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of rotigotine on Parkinson's disease-related sleep disturbances.
    Antonini A; Calandrella D; Merello M; Koutsikos K; Pilleri M
    Expert Opin Pharmacother; 2013 Dec; 14(18):2571-80. PubMed ID: 24138154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.
    Babic T; Boothmann B; Polivka J; Rektor I; Boroojerdi B; Häck HJ; Randerath O
    Clin Neuropharmacol; 2006; 29(4):238-42. PubMed ID: 16855426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and SAR study of a novel series of dopamine receptor agonists.
    Risgaard R; Jensen M; Jørgensen M; Bang-Andersen B; Christoffersen CT; Jensen KG; Kristensen JL; Püschl A
    Bioorg Med Chem; 2014 Jan; 22(1):381-92. PubMed ID: 24296012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rotigotine transdermal delivery for the treatment of restless legs syndrome.
    Sixel-Döring F; Trenkwalder C
    Expert Opin Pharmacother; 2010 Mar; 11(4):649-56. PubMed ID: 20163275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebellar theta burst stimulation modulates short latency afferent inhibition in Alzheimer's disease patients.
    Di Lorenzo F; Martorana A; Ponzo V; Bonnì S; D'Angelo E; Caltagirone C; Koch G
    Front Aging Neurosci; 2013; 5():2. PubMed ID: 23423358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
    Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
    Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment with rotigotine in drug-naïve PSP patients.
    Schirinzi T; Pisani V; Imbriani P; Di Lazzaro G; Scalise S; Pisani A
    Acta Neurol Belg; 2019 Mar; 119(1):113-116. PubMed ID: 30062400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.
    Eskow Jaunarajs KL; Standaert DG; Viegas TX; Bentley MD; Fang Z; Dizman B; Yoon K; Weimer R; Ravenscroft P; Johnston TH; Hill MP; Brotchie JM; Moreadith RW
    Mov Disord; 2013 Oct; 28(12):1675-82. PubMed ID: 24014074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.
    Stiasny-Kolster K; Berg D; Hofmann WE; Berkels R; Grieger F; Lauterbach T; Schollmayer E; Bachmann CG
    Sleep Med; 2013 Jun; 14(6):475-81. PubMed ID: 23668924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New drugs: retapamulin, bismuth subcitrate potassium, and rotigotine.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(4):539-43. PubMed ID: 17616504
    [No Abstract]   [Full Text] [Related]  

  • 40. Rotigotine, a dopamine receptor agonist, increased BDNF protein levels in the rat cortex and hippocampus.
    Adachi N; Yoshimura A; Chiba S; Ogawa S; Kunugi H
    Neurosci Lett; 2018 Jan; 662():44-50. PubMed ID: 28993209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.